At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Post-Mkt 06-25 16:30:11 EDT
352.82
+1.39
+0.40%
盘后354.64
+1.82+0.52%
16:29 EDT
High359.10Low350.06Vol2.33M
Open350.06D1 Closing351.43Amplitude2.57%
Mkt Cap189.99BTradable Cap189.46BTotal Shares538.48M
T/O823.97MT/O Rate0.43%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

The Dow Hits Record High, Caterpillar Surges Over 5%
Tiger Newspress  ·  06-25 22:39
The Dow Hits Record High, Caterpillar Surges Over 5%
One-Time Windfalls for Listed Companies Are Not Sound Medium-to-Long-Term Investment Triggers
Deep News  ·  06-25 19:11
One-Time Windfalls for Listed Companies Are Not Sound Medium-to-Long-Term Investment Triggers
Sino Biopharmaceutical Stock Sheds 3.4% in Hong Kong, Underperforms Competitors
Dow Jones  ·  06-25 16:31
Sino Biopharmaceutical Stock Sheds 3.4% in Hong Kong, Underperforms Competitors
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  06-25 04:34
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Tango Therapeutics appoints Robert Azelby to board of directors
Reuters  ·  06-23
Tango Therapeutics appoints Robert Azelby to board of directors
Amgen-backed real-world study finds thyroid eye disease progression risk nears 40% by year eight
Reuters  ·  06-23
Amgen-backed real-world study finds thyroid eye disease progression risk nears 40% by year eight
Dow Up 263 Points On Gains For Shares Of Caterpillar, Visa
Dow Jones  ·  06-22
Dow Up 263 Points On Gains For Shares Of Caterpillar, Visa
Sino Biopharmaceutical Stock Slips 2.8% in Hong Kong, Underperforms Competitors
Dow Jones  ·  06-22
Sino Biopharmaceutical Stock Slips 2.8% in Hong Kong, Underperforms Competitors
AbbVie Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  06-19
AbbVie Inc. Stock Outperforms Competitors Despite Losses On The Day
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says
MT Newswires Live  ·  06-19
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says
Amgen Inc. Stock Underperforms Wednesday When Compared To Competitors
Dow Jones  ·  06-18
Amgen Inc. Stock Underperforms Wednesday When Compared To Competitors
Sino Biopharmaceutical Stock Slides 1.9% in Hong Kong
Dow Jones  ·  06-17
Sino Biopharmaceutical Stock Slides 1.9% in Hong Kong
Amgen price target raised to $303 from $295 at Mizuho
TIPRANKS  ·  06-16
Amgen price target raised to $303 from $295 at Mizuho
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation
Reuters  ·  06-16
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)
TIPRANKS  ·  06-16
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  06-16
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board
Reuters  ·  06-15
Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board
FACTBOX-Global drugmakers invest billions to boost US presence
Reuters  ·  06-15
FACTBOX-Global drugmakers invest billions to boost US presence
Sino Biopharmaceutical Stock Climbs 1.7% in Hong Kong, Outperforms Competitors
Dow Jones  ·  06-15
Sino Biopharmaceutical Stock Climbs 1.7% in Hong Kong, Outperforms Competitors
HBM Holdings-B Prevails in Patent Infringement Case Against Amgen, Awarded Approximately $20.2 Million with Potential for Triple Damages
Stock News  ·  06-15
HBM Holdings-B Prevails in Patent Infringement Case Against Amgen, Awarded Approximately $20.2 Million with Potential for Triple Damages

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--